金融商品のアラートを作成するための参加
経済指標と以下の著者によるコンテンツ
無料登録 すでにアカウントがありますか？ ログイン
50%引き！ InvestingProで2025年の市場を超える投資成績を
特別セールを請求する
204.610
+1.510
+0.74%
23/12 - 終了. EUR 通貨
- モーニングスターの評価:
- 総資産: 257.44M
Allianz Biotechnologie A EUR
204.610
+1.510
+0.74%
0P00000CML 概要
このページではAllianz Biotechnologie A EURの基本的な企業情報をご覧になれます。 0P00000CML の主要な経営陣、総資産、投資戦略、連絡先情報など。
連絡先
住所
L-2633 Senningerberg
Frankfurt am Main, 60323
Germany
Frankfurt am Main, 60323
Germany
電話
+49 (0) 69 2443-1140
ファクス
Milano
役員トップ
| 銘柄 | タイトル | 以来 | まで |
|---|---|---|---|
| Christopher Chin | - | 2018 | now |
| Peter Pirsch | Senior Portfolio Manager | 2019 | 2023 |
| 伝記 | Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder. | ||
| Kimberlee W. Millar | Vice President | 2018 | 2021 |
| 伝記 | Ms. Millar is a portfolio manager, analyst and director with Allianz Global Investors, which she joined in 2005. As a generalist for the Disciplined Equities group, her primary responsibility is conducting company research; she also helps improve the group’s overall investment processes and contributes toward its portfolio-management efforts. Ms. Millar has 23 years of investment industry experience. She previously worked as an assistant economist at the Investment Company Institute in Washington, D.C., producing mutual-fund-industry research for investment-management firms’ research and marketing departments. Before that, Ms. Millar worked at Heiden Associates Inc., an economic consulting firm in Washington, D.C. She has a B.A. in economics from the University of Calgary, Canada, and an M.A. in economics from Queen’s University, Canada. Ms. Millar is a CFA charterholder and a member of the CFA Institute. | ||
| Hugo Ong | - | 2018 | 2021 |
| Peter Pirsch | Senior Portfolio Manager | 2018 | 2019 |
| 伝記 | Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder. | ||
| John R. Schroer | Portfolio Manager | 2014 | 2018 |
| 伝記 | Mr. Schroer, CFA, is a portfolio manager and a director with Allianz Global Investors, which he joined in 2014. He is the sector head of the Health Care team. He was previously the president of Schroer Capital, L.P.; an equity analyst with HealthCor Management, L.P.; a managing member and portfolio manager for ITROS Capital Management, LLC; a global partner, senior vice president, and portfolio manager for INVESCO; and an analyst for Trust Company of the West. Mr. Schroer has a B.S. in history and international relations and an M.B.A. in finance from the University of Wisconsin. | ||
| Paul A. Wagner | Senior Research Analyst | 2012 | 2014 |
| 伝記 | Mr. Wagner, CFA, is a portfolio manager, a senior research analyst and a director with Allianz Global Investors, which he joined in 2006. He has biotechnology responsibilities for the US Health Care team and has 14 years of investment-industry experience. Mr. Wagner previously worked at PDL BioPharma in corporate and business development, and was a vice president and senior equity-research analyst in the biotechnology sector at Lehman Brothers. He has a B.S. in chemistry from the University of Wisconsin and a Ph.D. in chemistry from the California Institute of Technology. | ||
| Nicole Papassavvas | - | 2008 | 2012 |
| Javier Latorre | - | 2007 | 2012 |
Allianz Biotechnologie A EURについての考えを書いてください
本当にこのチャートを削除しますか
削除 キャンセル
添付のチャートを新しいチャートと置き換えますか？
置き換える キャンセル
コメントガイドライン
コメントにチャートを挿入する
ブロックを確認
本当に%USER_NAME%をブロックしたいですか。
ブロックすると、あなたと%USER_NAME%はお互いのInvesting.comへの投稿を見ることができなくなります。
%USER_NAME%は無事ブロックリストに追加されました
この人のブロックを解除したばかりなので、再度ブロックするには48時間待つ必要があります。
このコメントを報告してください
このコメントについて下記のように感じます
コメントに印がつきました
ありがとうございます!
報告は、確認のため管理担当に送られました